Capricor Therapeutics (CAPR) Interest Expenses (2013 - 2017)
Capricor Therapeutics (CAPR) posted quarterly Interest Expenses of $614675.0 for Q1 2026, up 170.54% year-over-year from $227201.0 in Q1 2025, and up 148.39% quarter-over-quarter from $247466.0 in Q4 2025.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Interest Expenses (2013 - 2017) Analysis & Trends
Capricor Therapeutics' Interest Expenses history runs 14 years deep, the most recent figure standing at $614675.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 170.54% year-over-year to $614675.0; the TTM figure through Mar 2026 stood at $412421.0 (up 140.64% YoY), while the FY2025 annual figure was $278.2 million, up 173.29% from the prior year.
- Interest Expenses for Q1 2026 stood at $614675.0, up from $247466.0 in the prior quarter.
- The five-year high for Interest Expenses was $118.5 million in Q3 2024, with the low at -$676921.0 in Q4 2024.
- The 5-year median for Interest Expenses is $3.7 million (2023), against an average of $17.2 million.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 226.8% in 2023, then jumped 96505.09% in 2024.
- Capricor Therapeutics' Interest Expenses stood at $470950.0 in 2022, then tumbled by 226.8% to -$597173.0 in 2023, then retreated by 13.35% to -$676921.0 in 2024, then jumped by 136.56% to $247466.0 in 2025, then surged by 148.39% to $614675.0 in 2026.
- Business Quant data shows CAPR's Interest Expenses at $614675.0 in Q1 2026, $247466.0 in Q4 2025, and $33.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 80,307.00 |
| Sep 30, 2017 | 107,653.00 |
| Jun 30, 2017 | 105,527.00 |
| Mar 31, 2017 | 105,320.00 |
| Dec 31, 2016 | 102,905.00 |
| Sep 30, 2016 | 98,749.00 |
| Jun 30, 2016 | 76,887.00 |
| Mar 31, 2016 | 66,125.00 |
| Dec 31, 2015 | 63,583.00 |
| Sep 30, 2015 | 61,681.00 |
| Jun 30, 2015 | 61,681.00 |
| Mar 31, 2015 | 61,681.00 |
| Dec 31, 2014 | 60,383.00 |
| Sep 30, 2014 | 60,091.00 |
| Jun 30, 2014 | 54,704.00 |
| Mar 31, 2014 | 25,327.00 |
| Dec 31, 2013 | 24,859.00 |
| Sep 30, 2013 | 23,353.00 |
| Jun 30, 2013 | 6,211.00 |
| Mar 31, 2013 | 3,711.00 |